The Fine Art and Science of Translating Trials Results Into Clinical Practice
Over 2 decades ago, the mineralocorticoid receptor antagonist (MRA), spironolactone was demonstrated to substantially reduce the risk of all-cause mortality along with heart failure (HF) hospitalizations in patients with HF with reduced ejection fraction (HFrEF) enrolled in the Randomized Aldactone…